HLS – Macquarie rates the stock as Outperform

By Broker News | More Articles by Broker News

Macquarie reviews the pathology margins, noting these have declined over time but expansion is now likely to FY23.

Contributions from Covid-19 testing as well as a recovery in base volumes are positive indicators going forward. There is also opportunities for growth, given an improved balance sheet.

A demonstration of operating leverage within pathology will be a catalyst for a multiple re-rating, in the broker’s view. Outperform retained. Target rises to $3.80 from $3.70.

Sector: Health Care Equipment & Services.

Target price is $3.80.Current Price is $3.33. Difference: $0.47 – (brackets indicate current price is over target). If HLS meets the Macquarie target it will return approximately 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →